Analysts await The Medicines Company (NASDAQ:MDCO) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.85 EPS, down 97.65% or $0.83 from last year’s $-0.02 per share.

At the moment 11 analysts are watching The Medicines Company (NASDAQ:MDCO), 4 rate it “Buy”, 5 “Outperform”, 2 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 9 analysts have a mean sales target of 49.85 million. For the quarter ending Sep-16, 9 analysts have a mean sales target of 50.82 million whilst for the year ending Dec-16, 9 analysts have a mean target of 201.60 million.

In terms of earnings per share, 8 analysts have a -0.90 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 8 analysts have a -0.94 EPS mean target and for the quarter ending Sep-16 there are 8 estimates of -3.62 EPS.

The biggest institutional shareholders in The Medicines Company include Fidelity Management and Research Company which owns 10 million shares in the company valued at $390.50 million. Wellington Management Company LLP is the second biggest holder with 10 million shares currently valued at 362.84 million whilst BlackRock Fund Advisors has 5 million shares valued at 201.53 million.

Total shares held by institutions as of the most recent company filings are 80,661,265 with a reported 6,867,435 bought and 7,921,400 sold. These holdings make up 99.53% of the company’s outstanding shares.

Currently insiders hold 1,240,000 shares in the business which makes up 1.78% of shares. The biggest holder currently is Dr. Clive A. Meanwell,M.D. who owns 338,790 shares (0.49% of those outstanding), whilst Dr. Armin M. Kessler holds 136,830 (0.20% of shares outstanding) and Robert J. Hugin holds 101,470 (0.15% of shares outstanding).

The stock increased 3.46% or $1.21 during the last trading session, hitting $40.94. The Medicines Company (NASDAQ:MDCO) has risen 3.08% over the past 6 months and is uptrending.